Biogen Inc. (BIIB), a leading growth investor stock, continues to make significant strides. The company recently received approval for its Alzheimer's drug, Leqembi, from Great Britain and Israel, showing considerable traction in the market. Biogen strengthened its late-stage pipeline by acquiring
Human Immunology Biosciences and expanding its immunology portfolio. It also revealed positive results from the higher dose regimen study of
Nusinersen, expressly beneficial in treating SMA. Its good Q3 performance resulted in a raised annual profit outlook. The company suffered some losses, as its
Leqembi sales were slow and the
price target had to be lowered from $251 to $207 at Mizuho. Negative analysts projections of flat revenue until 2026 dim Biogen's outlook. In addition, Primecap Management Co. CA and Natixis Advisors LLC sold significant shares. However, the company seems undervalued, and there is potential for a trend reversal. The treatments for CNS and genomics make Biogen an attractive investment option. It has also been given a favorable verdict on its Aflibercept Biosimilar, OPUVIZ, by Samsung Bioepis and CHMP. Its collaboration with
Ionis generated positive topline phase 1/2 study results of a drug for ALS, and
Sage Therapeutics resulted in a promising study of SAGE-324 (BIIB124) for Essential Tremor.
Biogen BIIB News Analytics from Wed, 31 Jan 2024 08:00:00 GMT to Sat, 23 Nov 2024 09:14:42 GMT -
Rating 2
- Innovation 5
- Information 6
- Rumor -3
